Abstract
The biological effects of dehydrodidemnin B(DDB), a novel depsipeptide isolated from Aplidium albicans, were studied on Ehrlich carcinoma growing in vivo and in primary cultures, and compared with those reported for Didemnin B (DB). Daily administration of DB or DDB (2.5 micrograms/mouse) almost duplicated the animal life-span and total number of tumour cells decreased by 70-90%. Results suggest a major effect of DDB when administered in the lag phase of growth. DDB behaved as a very potent inhibitor of protein synthesis; consequently, ornithine decarboxylase activity (ODC, EC 4.1.1.17) is drastically reduced by DDB-treatment.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Carcinoma, Ehrlich Tumor / drug therapy*
-
Carcinoma, Ehrlich Tumor / metabolism
-
Cell Division / drug effects
-
Cell Survival / drug effects
-
Depsipeptides*
-
Drug Screening Assays, Antitumor
-
Enzyme Induction / drug effects
-
Mammary Neoplasms, Experimental / drug therapy*
-
Mammary Neoplasms, Experimental / metabolism
-
Mice
-
Neoplasm Proteins / biosynthesis
-
Ornithine Decarboxylase / biosynthesis
-
Ornithine Decarboxylase / drug effects
-
Peptides, Cyclic / pharmacology*
-
Sulfur Radioisotopes
-
Urochordata / chemistry
Substances
-
Antineoplastic Agents
-
Depsipeptides
-
Neoplasm Proteins
-
Peptides, Cyclic
-
Sulfur Radioisotopes
-
didemnins
-
Ornithine Decarboxylase
-
plitidepsin